AIM
ALNY icon

AIA Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

AIA Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$24K Hold
167
– – 0.01% 371
2020
Q2 		$25K Buy
+167
New +$22.5K 0.01% 308

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

AIA Investment Management's ALNY Position: Q3 2020 in Review

AIA Investment Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2020 at 167 shares worth $24K. The position accounts for 0.01% of the portfolio, ranked #371.

AIA Investment Management first reported a position in ALNY in Q2 2020 and has held it in 2 quarters since. The position peaked at $25K in Q2 2020. 356 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

  • AIA Investment Management held 167 shares of Alnylam Pharmaceuticals worth $24K as of Q3 2020.
  • AIA Investment Management left its Alnylam Pharmaceuticals share count unchanged in Q3 2020.
  • Alnylam Pharmaceuticals made up 0.01% of AIA Investment Management's portfolio in Q3 2020, its #371 holding.
  • AIA Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
  • AIA Investment Management's Alnylam Pharmaceuticals position peaked at $25K in Q2 2020.
  • 356 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on AIA Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.